Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Low doses of the antidepressant mirtazapine or the neuroleptic quetiapine are often prescribed off-label for insomnia. However, studies on the effects on sleep and hangover effects the following day are scarce. In this randomised, double-blind, cross-over, placebo-controlled trial, the influence of 7.5 mg mirtazapine and 50 mg quetiapine on both normal sleep and sleep disturbed by acoustic stress (traffic noise) as a model for transient insomnia was assessed. Additionally, hangover effects on next-day alertness and cognitive functioning were examined. A total of 19 healthy men without sleep complaints completed three treatment sessions, each session consisting of three consecutive nights in one of the mirtazapine, quetiapine or placebo conditions. Sleep was assessed using polysomnography and the Leeds Sleep Evaluation Questionnaire. Daytime sleepiness and cognitive functioning were assessed using the Leeds Sleep Evaluation Questionnaire, Karolinska Sleepiness Scale, Digit Symbol Substitution Task, Psychomotor Vigilance Task and an addition task. Under acoustic stress, both mirtazapine and quetiapine increased total sleep time by half an hour and reduced the number of awakenings by 35–40% compared to placebo. While quetiapine specifically increased the duration of non-rapid eye movement sleep, stage N2, mirtazapine mainly increased deep sleep stage N3. Subjects reported that both mirtazapine and quetiapine eased getting to sleep and improved sleep quality. Both drugs caused daytime sleepiness and lessened sustained attention. These findings support the use of low doses of mirtazapine and quetiapine for the treatment of insomnia. Further prospective studies on the long-term effects regarding effectiveness and adverse effects are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subjective and objective sleepiness in the active individual
Åkerstedt, T., & Gillberg, M. (1990) · International Journal of Neuroscience · doi:10.3109/00207459008994241 · Cited by 3,088 · cited 4×
“Karolinska Sleepiness Scale (KSS).”
MethodInfluentialInternational Classification of Sleep Disorders
Thorpy, M. (2017) · Sleep Disorders Medicine · doi:10.1007/978-1-4939-6578-6_27 · Cited by 2,505
Tononi, G., & Cirelli, C. (2014) · Neuron · doi:10.1016/j.neuron.2013.12.025 · Cited by 2,356 · cited 1×
“EEG slow waves, which mainly occur during N3, are generally thought to be of major importance for recovery from preceding wakefulness, for instance in the synaptic homeostasis hypothesis (Tononi and Cirelli, 2014).”
BackgroundSerotonin control of sleep-wake behavior
Monti, J. M. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.11.003 · Cited by 614
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Wu, J. Q., Appleman, E. R., Salazar, R. D., & Ong, J. C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.3006 · Cited by 527 · cited 1×
“Recent meta-analyses showed that the latter is an efficacious therapy for insomnia, including insomnia comorbid with mental disorders and, to a smaller extent, medical diseases (Wu et al., 2015).”
BackgroundRiemann, D., & Perlis, M. L. (2009) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2008.06.001 · Cited by 477 · cited 1×
“The first treatment option consists of nonpharmacological therapy, e.g. addressing sleep hygiene behaviour or cognitive behavioural therapy for insomnia (Riemann and Perlis, 2009).”
BackgroundSleep Disturbances in Patients with Schizophrenia: Impact and Effect of Antipsychotics
Cohrs, S. (2008) · CNS Drugs · doi:10.2165/00023210-200822110-00004 · Cited by 433 · cited 2×
“Subjectively reported sleep complaints in mentally disordered people are largely supported by aberrants in polysomnographic analyses (Argyropoulos and Wilson, 2005; Cohrs, 2008; Monti and Monti, 2004; Thase, 2006).”
BackgroundOhayon, M. M., & Reynolds, C. F. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.07.008 · Cited by 432 · cited 1×
“General population estimates range from 7% to well over 30%, depending on the employed definition and instruments (Ohayon and Reynolds, 2009; Roth et al., 2011).”
BackgroundBenzodiazepines: Risks and Benefits. A Reconsideration
Baldwin, D. S., Aitchison, K., Bateson, A., Curran, H. V., Davies, S., Leonard, B., Nutt, D. J., Stephens, D. N., & Wilson, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503509 · Cited by 249 · cited 1×
“However, there are cases when longer term use is justifiable and ultimately the assessment of the benefits and risks of benzodiazepines is a matter of clinical judgement (Baldwin et al., 2013).”
Background
Cited by
Wilson, S., Anderson, K., Baldwin, D., Dijk, D.-J., Espie, A., Espie, C., Gringras, P., Krystal, A., Nutt, D., Selsick, H., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855343 · Cited by 312
Prado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Saif, N., Yan, P., Niotis, K., Scheyer, O., Rahman, A., Berkowitz, M., Krikorian, R., Hristov, H., Sadek, G., Bellara, S., et al. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.39 · Cited by 41
2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association
Drager, L. F., Assis, M., Bacelar, A. F. R., Poyares, D. L. R., Conway, S. G., Pires, G. N., de Azevedo, A. P., Carissimi, A., Eckeli, A. L., Pentagna, Á., et al. (2023) · Sleep Science · doi:10.1055/s-0043-1776281 · Cited by 25
Metadata
- Authors
- Karsten, J., Hagenauw, L. A., Kamphuis, J., & Lancel, M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-01-16
- Volume
- 31
- Issue
- 3
- Pages
- 327-337
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2571834479
- Cited by
- 72
- References
- 17
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. https://app.cochat.ai/papers/10.1177/0269881116681399
- The paper
- Karsten, J., Hagenauw, L. A., Kamphuis, J., & Lancel, M. (2017). Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116681399
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.